Analyst Expectations for BioXcel Therapeutics's Future
Portfolio Pulse from Benzinga Insights
BioXcel Therapeutics (NASDAQ:BTAI) has received mostly bullish ratings from analysts in the last quarter, with 6 bullish ratings and 1 indifferent. The average 12-month price target for the company, according to 7 analysts, is $49.86, which has increased by 28.94% over the past month.
June 30, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics has received mostly bullish ratings from analysts, which could positively impact its stock price.
Analyst ratings often influence investor sentiment and can impact a company's stock price. Given the mostly bullish ratings for BioXcel Therapeutics, this could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100